A randomized, prospective, multicenter, controlled and double-blinded Phase II Clinical Trial to evaluate the influence of inhaled Aviptadil on Cough and Quality of Life in Sarcoidosis patients
Latest Information Update: 20 Sep 2024
Price :
$35 *
At a glance
- Drugs Aviptadil (Primary)
- Indications Cough; Pulmonary sarcoidosis
- Focus Therapeutic Use
- Acronyms Avisarco II
- 20 Sep 2024 Status changed from recruiting to completed.
- 25 Mar 2021 New trial record